io-202
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2020 (NCT04372433)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
antagonist - LILRB4
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05309187 | Phase 1 | Apr 30, 2022 | Immune-Onc Therapeutics Inc |
| NCT04372433 | Phase 1 | Jul 31, 2020 | Immune-Onc Therapeutics Inc |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Immune-Onc Therapeutics Inc | For profit | 2 | 2 | 1 | 2020 |
1 organizations
Page 1 / 1